Yes, Z79.4 is a billable/specific ICD-10-CM code that can be used for reimbursement purposes as either a primary or secondary diagnosis
In short: GLP-1/GIP therapies improve body composition , helping you lose fat while maintaining and often improving your lean-mass ratio and muscle function
10.1155/2019/7167525 [DOI] [PMC free article] [PubMed] [Google Scholar] Kuang H., Zhao D., Tian Z., Liu Z., Dai S., Zheng Y., et al
One expected outcome of this effect is the GRK2-mediated modulation of -arrestin-mediated desensitization and thus of the canonical GLP-1R-dependent signaling pathways known to modulate insulin release
Dasatinib has shown antifibrotic effects in keloid fibroblasts and xenotransplant keloid tissue in mice through the selective clearance of senescent cells and modulation of SASP, implying that dasatinib can be possibly used for senolytic treatment of keloids 15